Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097545260> ?p ?o ?g. }
- W2097545260 endingPage "169" @default.
- W2097545260 startingPage "156" @default.
- W2097545260 abstract "Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic lymphocytic leukemia (CLL), both as a single agent and in combination with traditional chemotherapies. The modest activity demonstrated in early studies evaluating rituximab in relapsed CLL was improved with higher doses or more dose-intensive regimens that overcame the unfavorable pharmacokinetic features commonly found in CLL. These studies led to a variety of combination trials of rituximab with chemotherapy, where both phase II and later phase III studies have shown great promise for the advancement of CLL therapy. Despite the therapeutic success of rituximab in CLL, studies demonstrating the definitive relative mechanism of tumor clearance are still lacking and this requires further investigation. In addition to being used as a therapy for CLL, rituximab is an effective treatment for autoimmune CLL complications such as hemolytic anemia and immune thrombocytopenia (ITP). Patients with CLL may experience early infusion-related side effects that can be diminished with corticosteroid pretreatment and stepped-up dosing. Risk factors for infusion-related toxicity may relate to atypical CLL expressing bright CD20 antigen expression, although several different studies have not clearly implicated elevated white blood cell count as a risk factor. Other adverse events, including delayed cytopenias, reactivation of hepatitis B, and development of progressive multifocal leukoencephalopathy, are rare. Future efforts focusing on novel combination-based strategies will be required to fully appreciate the benefit of this therapy in CLL." @default.
- W2097545260 created "2016-06-24" @default.
- W2097545260 creator A5000921376 @default.
- W2097545260 creator A5072835425 @default.
- W2097545260 date "2010-04-01" @default.
- W2097545260 modified "2023-10-04" @default.
- W2097545260 title "Rituximab in Chronic Lymphocytic Leukemia" @default.
- W2097545260 cites W1243376384 @default.
- W2097545260 cites W137167786 @default.
- W2097545260 cites W1429374962 @default.
- W2097545260 cites W1499230593 @default.
- W2097545260 cites W1511416976 @default.
- W2097545260 cites W1553227584 @default.
- W2097545260 cites W1580026313 @default.
- W2097545260 cites W1643400449 @default.
- W2097545260 cites W1685882185 @default.
- W2097545260 cites W1732341950 @default.
- W2097545260 cites W1829598765 @default.
- W2097545260 cites W1915689252 @default.
- W2097545260 cites W1935886040 @default.
- W2097545260 cites W1942856476 @default.
- W2097545260 cites W1952288345 @default.
- W2097545260 cites W1965962344 @default.
- W2097545260 cites W1968458944 @default.
- W2097545260 cites W1971850723 @default.
- W2097545260 cites W1973810603 @default.
- W2097545260 cites W1973956439 @default.
- W2097545260 cites W1978235999 @default.
- W2097545260 cites W1980038080 @default.
- W2097545260 cites W1985460392 @default.
- W2097545260 cites W1985807069 @default.
- W2097545260 cites W1985871504 @default.
- W2097545260 cites W1988217711 @default.
- W2097545260 cites W1994820184 @default.
- W2097545260 cites W1996008853 @default.
- W2097545260 cites W1997131599 @default.
- W2097545260 cites W2001014409 @default.
- W2097545260 cites W2001850157 @default.
- W2097545260 cites W2001934131 @default.
- W2097545260 cites W2005680325 @default.
- W2097545260 cites W2006128121 @default.
- W2097545260 cites W2008472399 @default.
- W2097545260 cites W2009593167 @default.
- W2097545260 cites W2010244981 @default.
- W2097545260 cites W2010450410 @default.
- W2097545260 cites W2013691481 @default.
- W2097545260 cites W2016904449 @default.
- W2097545260 cites W2020314417 @default.
- W2097545260 cites W2021830136 @default.
- W2097545260 cites W2022669864 @default.
- W2097545260 cites W2026636367 @default.
- W2097545260 cites W2029903885 @default.
- W2097545260 cites W2032423298 @default.
- W2097545260 cites W2033315156 @default.
- W2097545260 cites W2034168567 @default.
- W2097545260 cites W2042521757 @default.
- W2097545260 cites W2043220369 @default.
- W2097545260 cites W2044360617 @default.
- W2097545260 cites W2046221853 @default.
- W2097545260 cites W2052346599 @default.
- W2097545260 cites W2052722931 @default.
- W2097545260 cites W2053683902 @default.
- W2097545260 cites W2059227619 @default.
- W2097545260 cites W2059800699 @default.
- W2097545260 cites W2062395913 @default.
- W2097545260 cites W2063792914 @default.
- W2097545260 cites W2066388140 @default.
- W2097545260 cites W2066485964 @default.
- W2097545260 cites W206701898 @default.
- W2097545260 cites W2069524809 @default.
- W2097545260 cites W2070003264 @default.
- W2097545260 cites W2070193300 @default.
- W2097545260 cites W2072620152 @default.
- W2097545260 cites W2073024643 @default.
- W2097545260 cites W2073873436 @default.
- W2097545260 cites W2078493126 @default.
- W2097545260 cites W2095058829 @default.
- W2097545260 cites W2095119858 @default.
- W2097545260 cites W2099308699 @default.
- W2097545260 cites W2099348990 @default.
- W2097545260 cites W2100309290 @default.
- W2097545260 cites W2104940816 @default.
- W2097545260 cites W2107567250 @default.
- W2097545260 cites W2107615815 @default.
- W2097545260 cites W2112476236 @default.
- W2097545260 cites W2116095933 @default.
- W2097545260 cites W2116262245 @default.
- W2097545260 cites W2117648265 @default.
- W2097545260 cites W2120755425 @default.
- W2097545260 cites W2123187146 @default.
- W2097545260 cites W2123363238 @default.
- W2097545260 cites W2123880240 @default.
- W2097545260 cites W2125134816 @default.
- W2097545260 cites W2126442701 @default.
- W2097545260 cites W2129041705 @default.
- W2097545260 cites W2132433919 @default.
- W2097545260 cites W2135270635 @default.
- W2097545260 cites W2136350611 @default.